Table 1.

Demographics of study population

Whole population (n = 259)Azacitidine alone (n = 129)Azacitidine + Vorinostat (n = 130)
No. (%)No. (%)No. (%)
Age, years
 <70 years old96 (37)48 (37)48 (37)
 ≥70 years old163 (63)81 (63)82 (63)
Gender
 Male156 (60)75 (58)81 (62)
 Female103 (40)54 (42)49 (38)
AML disease stage
 Newly diagnosed111 (43)57 (44)54 (42)
 Relapsed73 (28)34 (26)39 (30)
 Refractory33 (13)17 (13)16 (12)
MDS disease stage
 Newly diagnosed36 (14)16 (12)20 (15)
 Relapsed5 (2)4 (3)1 (1)
 Refractory1 (0)1 (1)0 (0)
ECOG performance status
 084 (32)52 (40)32 (25)
 1133 (51)63 (49)70 (54)
 226 (10)9 (7)17 (13)
 Missing16 (6)5 (4)11 (8)
Cytogenetic group
 Favorable risk13 (5)2 (2)11 (8)
 Intermediate risk109 (42)58 (45)51 (39)
 Poor risk54 (21)26 (20)28 (22)
 Risk not known/not done73 (28)38 (29)35 (27)
 Missing10 (4)5 (4)5 (4)
BM morphology, % blasts
 Mean46.24844.4
 SD28.427.729.1
Hemoglobin, g/L
 Mean131.1120.9141.1
 SD184.9167.5200.9
Platelets, 109/L
 Mean85.478.192.7
 SD131.279.2167.7
WCC, 109/L
 Mean14.115.612.6
 SD24.62919.4
Neutrophils, 109/L
 Mean3.133.2
 SD9.28.49.9